Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. (Q44955040)

7 December 2017

Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. (English)

1 reference

7 December 2017

5

Ljungman P

1 reference

7 December 2017

Avetisyan G

1

1 reference

7 December 2017

Aschan J

series ordinal

2

1 reference

7 December 2017

Hägglund H

series ordinal

3

1 reference

7 December 2017

Ringdén O

series ordinal

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

27 August 2007

1 reference

Bone Marrow Transplantation

7 December 2017

1 reference

7 December 2017

40

1 reference

7 December 2017

9

1 reference

7 December 2017

865-869

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705825

7 December 2017

0 references

cites work

Strategies for the prevention of cytomegalovirus disease after marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Clinical aspects of CMV infection after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Recent advances in the therapy and prevention of CMV infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705825

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705825

1 reference

Dimensions Publication ID

7 December 2017

0 references

1 reference